Trial · NCT03175367
Results by group81
Each measurement the trial posted, group by group, in the words and numbers it posted.
41 to 60 of 81
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With >= 50% Reduction in Calculated LDL-C at Week 16 (ITT Estimand) | Group B: Evinacumab 15 mg/kg IV Q4W (DBTP to OLTP) | 63.2 | Percentage of Participants | ||
| Percentage of Participants With Calculated LDL-C < 50 mg/dL (1.30 mmol/L) at Week 16 (ITT Estimand) | Group A: Placebo SC QW (DBTP) | 5.1 | Percentage of Participants | ||
| Percentage of Participants With Calculated LDL-C < 50 mg/dL (1.30 mmol/L) at Week 16 (ITT Estimand) | Group A: Evinacumab 300 mg SC Q2W (DBTP) | 22.8 | Percentage of Participants | ||
| Percentage of Participants With Calculated LDL-C < 50 mg/dL (1.30 mmol/L) at Week 16 (ITT Estimand) | Group A: Evinacumab 300 mg SC QW (DBTP) | 29.7 | Percentage of Participants | ||
| Percentage of Participants With Calculated LDL-C < 50 mg/dL (1.30 mmol/L) at Week 16 (ITT Estimand) | Group A: Evinacumab 450 mg SC QW (DBTP) | 40.8 | Percentage of Participants | ||
| Percentage of Participants With Calculated LDL-C < 50 mg/dL (1.30 mmol/L) at Week 16 (ITT Estimand) | Group B: Placebo IV Q4W (DBTP to OLTP) | 9.3 | Percentage of Participants | ||
| Percentage of Participants With Calculated LDL-C < 50 mg/dL (1.30 mmol/L) at Week 16 (ITT Estimand) | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP to OLTP) | 13.2 | Percentage of Participants | ||
| Percentage of Participants With Calculated LDL-C < 50 mg/dL (1.30 mmol/L) at Week 16 (ITT Estimand) | Group B: Evinacumab 15 mg/kg IV Q4W (DBTP to OLTP) | 39.5 | Percentage of Participants | ||
| Percent Change From Baseline in Calculated LDL-C at Week 24 (ITT Estimand) | Group B: Placebo IV Q4W (DBTP to OLTP) | 14.8 | Standard Error 8.3 | Percent Change | |
| Percent Change From Baseline in Calculated LDL-C at Week 24 (ITT Estimand) | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP to OLTP) | -17.7 | Standard Error 8.0 | Percent Change | |
| Percent Change From Baseline in Calculated LDL-C at Week 24 (ITT Estimand) | Group B: Evinacumab 15 mg/kg IV Q4W (DBTP to OLTP) | -39.7 | Standard Error 7.7 | Percent Change | |
| Percent Change From Baseline in Total Cholesterol (TC) at Week 16 (ITT Estimand) | Group A: Placebo SC QW (DBTP) | 6.1 | Standard Error 4.0 | Percent Change | |
| Percent Change From Baseline in Total Cholesterol (TC) at Week 16 (ITT Estimand) | Group A: Evinacumab 300 mg SC Q2W (DBTP) | -31.0 | Standard Error 4.0 | Percent Change | |
| Percent Change From Baseline in Total Cholesterol (TC) at Week 16 (ITT Estimand) | Group A: Evinacumab 300 mg SC QW (DBTP) | -40.3 | Standard Error 4.0 | Percent Change | |
| Percent Change From Baseline in Total Cholesterol (TC) at Week 16 (ITT Estimand) | Group A: Evinacumab 450 mg SC QW (DBTP) | -45.4 | Standard Error 3.9 | Percent Change | |
| Percent Change From Baseline in Total Cholesterol (TC) at Week 16 (ITT Estimand) | Group B: Placebo IV Q4W (DBTP to OLTP) | -0.4 | Standard Error 4.5 | Percent Change | |
| Percent Change From Baseline in Total Cholesterol (TC) at Week 16 (ITT Estimand) | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP to OLTP) | -22.6 | Standard Error 4.4 | Percent Change | |
| Percent Change From Baseline in Total Cholesterol (TC) at Week 16 (ITT Estimand) | Group B: Evinacumab 15 mg/kg IV Q4W (DBTP to OLTP) | -46.8 | Standard Error 4.1 | Percent Change | |
| Percent Change From Baseline in Total Cholesterol at Week 24 (ITT Estimand) | Group B: Placebo IV Q4W (DBTP to OLTP) | 8.5 | Standard Error 5.1 | Percent Change | |
| Percent Change From Baseline in Total Cholesterol at Week 24 (ITT Estimand) | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP to OLTP) | -19.9 | Standard Error 4.9 | Percent Change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03175367/results?page=3